September 20, 2021 Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
September 17, 2021 Vicore starts dosing of first COVID-19 patients in the global phase 3 trial ATTRACT-3
September 14, 2021 Nordic Nanovector Appoints Experienced Pharmaceutical Business Leader Erik Skullerud as Chief Executive Officer
September 14, 2021 Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021